Hermetica Superfood Encyclopedia
The Short Answer
Thalassiosira pseudonana synthesizes bioactive compounds including fucoxanthin, chrysolaminarin (a β-1,3-glucan accumulating at 20–25% of biomass), and omega-3-associated lipids through photosynthetic carbon fixation modeled by genome-scale metabolic networks comprising over 6,000 reactions. As of current scientific literature, no clinical trials or validated human nutritional applications exist for this organism, and its designation as a 'Vitamin C source for immune support' is not substantiated by published evidence.
CategoryOther
GroupMarine-Derived
Evidence LevelPreliminary
Primary KeywordThalassiosira pseudonana supplement
Thalassiosira pseudonana — botanical close-up
Health Benefits
**Chrysolaminarin (β-1,3-glucan) Production**: T
pseudonana accumulates chrysolaminarin at 20–25% of its ash-free dry weight, a β-1,3-linked glucan structurally related to immunomodulatory polysaccharides studied in other organisms; human efficacy from this specific diatom source is unconfirmed.
**Fucoxanthin Biosynthesis Potential**
The organism biosynthesizes fucoxanthin, a marine carotenoid that in other algal species has demonstrated antioxidant and anti-inflammatory properties in preclinical models; T. pseudonana-derived fucoxanthin has not been tested in human trials.
**Omega-3 and Lipid Profile**: Under elevated CO₂ (1–5%), T
pseudonana doubles its lipid content, producing a fatty acid profile rich in palmitoleic acid (16:1) and oleic acid (18:1); these lipids hold theoretical nutritional relevance but have not been evaluated in human dietary studies.
**Cobalamin (Vitamin B12) Dependency**: T
pseudonana is a B12 auxotroph requiring external cobalamin for growth, indicating its metabolic coupling to this essential vitamin; however, this reflects the organism's requirement, not a delivery mechanism for human B12 supplementation.
**Biomass Productivity for Nutraceutical Extraction**
Cultivation under optimized CO₂ conditions yields 44–48 mg ash-free dry weight L⁻¹ day⁻¹, providing a potential biotechnological platform for extracting marine bioactives; downstream human applications remain at the research stage.
**Carbon Fixation and Metabolic Versatility**
Genome-scale models (iTps1432: 6,073 reactions, 2,789 metabolites) reveal robust Calvin-Benson-Bassham cycle activity and nutrient-responsive upregulation of neutral lipid and carbohydrate synthesis, suggesting metabolic flexibility exploitable for targeted compound production.
**Silica-Regulated Carbohydrate Accumulation**
Silicon limitation specifically upregulates chrysolaminarin accumulation and chlorophyll biosynthesis pathways, offering a controllable lever for enriching immunologically relevant polysaccharide fractions in cultivated biomass.
Origin & History
Natural habitat
Thalassiosira pseudonana is a unicellular marine diatom found in coastal and open-ocean environments worldwide, particularly in cold to temperate marine waters where silicic acid and nutrients are available. It thrives in photic zones where photosynthesis can occur, and under laboratory conditions it is cultivated in controlled photobioreactors with defined seawater-based media, regulated CO₂ concentrations (typically 1–5%), and artificial illumination. It holds the distinction of being the first diatom to have its genome fully sequenced (2004), making it a foundational model organism in marine biotechnology and phycology research.
“Thalassiosira pseudonana carries no history of use in any traditional medicine system, indigenous food culture, or ethnobotanical practice, as it was not isolated, identified, and cultivated as a distinct species until the modern era of marine microbiology. It gained scientific prominence in 2004 when the Joint Genome Institute published its fully sequenced genome, establishing it as the primary model organism for diatom biology and marine carbon cycling research. Its cultural significance is entirely academic and biotechnological — it has served as the reference organism for understanding marine primary productivity, silicon metabolism, and lipid biosynthesis in eukaryotic microalgae. There are no historical medicinal references, folk preparations, or ethnopharmacological records associated with this species.”Traditional Medicine
Scientific Research
The scientific literature on T. pseudonana consists entirely of in vitro cultivation studies, genomic analyses, and metabolic flux modeling — no human clinical trials, animal feeding studies, or ex vivo human tissue experiments have been published as of available evidence. Key studies include genome-scale metabolic reconstructions (iThaps987 with 987 genes, 2,477 reactions; iTps1432 with 6,073 reactions, 2,789 metabolites) that characterize photosynthetic and biosynthetic pathways without translating to clinical outcomes. Physiological experiments document growth rates of 1.14–1.29 divisions per day under high CO₂ and quantify chrysolaminarin accumulation at 20–25% biomass, but these metrics describe production potential rather than human health effects. The overall evidence base for any medicinal or nutritional application in humans is absent, placing this ingredient firmly in the speculative/biotechnological research phase with no peer-reviewed clinical substantiation.
Preparation & Dosage
Traditional preparation
**Laboratory Cultivation Form**
Grown in phototrophic seawater-based media (e.g., f/2 medium) under controlled illumination and 1–5% CO₂; no commercial supplement form exists.
**Biomass Harvest**
44–48 mg AFDW L⁻¹ day⁻¹; no standardized extract or dried powder formulation is commercially available
Achieved via centrifugation or filtration of liquid cultures yielding .
**No Established Human Dose**
No effective, safe, or recommended dose has been determined for any T. pseudonana preparation in humans; no clinical trial has established a dose-response relationship.
**Chrysolaminarin Fraction**
Theoretically extractable at 20–25% of biomass dry weight under silicon-limited cultivation, but no standardized extraction protocol for human supplement use has been validated.
**Traditional Preparation**
None — this organism has no history of traditional preparation or human consumption and is strictly a modern laboratory and biotechnology model organism.
Nutritional Profile
T. pseudonana biomass contains chrysolaminarin (β-1,3-glucan) at approximately 20–25% of ash-free dry weight, representing its most quantified bioactive carbohydrate fraction. Lipid content, while not precisely baseline-quantified, approximately doubles under 1–5% CO₂ cultivation, with a fatty acid profile dominated by monounsaturated fats including palmitoleic acid (16:1) and oleic acid (18:1), and reduced levels of saturated myristic acid (14:0) and polyunsaturated fatty acids under high CO₂ conditions. Fucoxanthin is present as a photosynthetic accessory pigment-carotenoid, though specific concentrations in T. pseudonana biomass have not been precisely reported in available literature. The organism requires exogenous cobalamin (Vitamin B12) for growth due to B12 auxotrophy, meaning it does not independently synthesize this vitamin. No validated data exist on protein content, amino acid profile, mineral composition, or bioavailability of any fraction for human consumption.
How It Works
Mechanism of Action
At the cellular level, T. pseudonana fixes carbon primarily through the C3/Calvin-Benson-Bassham cycle using linear electron flow in photosynthesis, with cyclic electron flow remaining largely inactive under standard growth conditions as revealed by genome-scale metabolic modeling. Under nitrogen, phosphorus, or silicon deprivation, the organism's metabolic flux shifts toward neutral lipid accumulation and carbohydrate storage (primarily chrysolaminarin), while carbon fixation rates and photorespiratory fluxes decrease — a nutrient-stress response potentially exploitable for enriching specific bioactive fractions. Chitin biosynthesis pathways are also encoded in the genome, contributing to cell wall architecture and potentially yielding chitin-derived nutraceutical precursors. No molecular mechanisms of action in human tissues, receptors, or enzyme systems have been established for any T. pseudonana-derived extract or fraction.
Clinical Evidence
No clinical trials investigating T. pseudonana as a dietary supplement, nutraceutical ingredient, or therapeutic agent in humans have been identified in the published literature. There are no measured clinical endpoints, effect sizes, biomarker changes, or safety observations from human subjects associated with consumption of this diatom or its extracts. The organism's compounds — particularly fucoxanthin and chrysolaminarin — have been studied clinically when derived from other algal sources (e.g., Undaria pinnatifida for fucoxanthin), but those findings cannot be directly extrapolated to T. pseudonana preparations. Confidence in any health claim for this specific microalgae as a human supplement ingredient is extremely low given the complete absence of human data.
Safety & Interactions
No human safety data, toxicology studies, maximum tolerated dose assessments, or adverse event reports exist for T. pseudonana or any preparation derived from it, as it has not been evaluated as a human food or supplement ingredient. Because it is cultivated in marine seawater-based media, potential contaminants could include heavy metals, marine toxins, or microbial pathogens if improperly processed — risks that have not been characterized under any regulatory framework. No drug interaction studies have been conducted, and no contraindications, pregnancy safety guidance, or lactation recommendations can be made based on available evidence. The claim that T. pseudonana serves as a 'Vitamin C source for immune support' is not supported by any published nutritional analysis or clinical evidence, and consumers should exercise significant caution regarding any commercial product making such assertions.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Thalassiosira pseudonana (Hustedt) Hasle & Heimdalcentric marine diatommodel diatom organismT. pseudonanaCyclotella nana (historical synonym)
Frequently Asked Questions
Is Thalassiosira pseudonana safe to take as a supplement?
No human safety data exist for Thalassiosira pseudonana as a dietary supplement, as it has never been evaluated in clinical toxicology or human consumption studies. Its cultivation in seawater-based media introduces potential risks of heavy metal or microbial contamination that have not been assessed under any food-safety regulatory framework, making its safety profile entirely unknown.
Does Thalassiosira pseudonana contain Vitamin C?
There is no published nutritional analysis confirming that Thalassiosira pseudonana is a meaningful source of Vitamin C (ascorbic acid) for human supplementation, and no clinical or biochemical studies have validated this claim. The organism is researched for its chrysolaminarin, fucoxanthin, and lipid content — not ascorbic acid — and any commercial claim positioning it as a Vitamin C source lacks peer-reviewed substantiation.
What bioactive compounds does Thalassiosira pseudonana produce?
T. pseudonana produces fucoxanthin (a carotenoid antioxidant pigment), chrysolaminarin (a β-1,3-glucan accumulating at 20–25% of biomass dry weight), and a lipid fraction rich in palmitoleic acid (16:1) and oleic acid (18:1) that increases under elevated CO₂ cultivation. These compounds have biotechnological interest for nutraceutical and biofuel applications, but none have been tested for efficacy or bioavailability in human subjects from this specific diatom source.
Has Thalassiosira pseudonana been studied in human clinical trials?
No human clinical trials have investigated Thalassiosira pseudonana or any extract derived from it for any health indication. All existing research consists of in vitro cultivation experiments, genome-scale metabolic modeling, and microbiological physiology studies, with no translation to human subjects, animal feeding trials, or even cell-based toxicity screening in human tissues reported in the available literature.
What is Thalassiosira pseudonana used for in research?
T. pseudonana is primarily used as a model organism in marine biology and biotechnology research, particularly for studying diatom photosynthesis, silicon metabolism, marine carbon fixation, and lipid biosynthesis pathways relevant to biofuel production. Its fully sequenced genome (published 2004) and comprehensive metabolic models — including iTps1432 with 6,073 biochemical reactions — make it invaluable for systems biology research, though these applications are entirely laboratory-based and do not translate to current clinical or nutritional supplement use.
How does Thalassiosira pseudonana compare to other marine microalgae supplements like spirulina or chlorella?
Thalassiosira pseudonana is a diatom microalgae distinct from spirulina (cyanobacteria) and chlorella (green algae) in its cellular structure and biochemical profile. While spirulina and chlorella are well-established supplements with extensive human studies, T. pseudonana is primarily used in research settings and is less commercially available as a finished supplement product. T. pseudonana's unique chrysolaminarin content (20–25% of dry weight) differentiates it from other microalgae, though human efficacy data specifically from this diatom source remains limited compared to spirulina and chlorella.
What is the bioavailability of chrysolaminarin from Thalassiosira pseudonana supplements?
The bioavailability of chrysolaminarin from T. pseudonana has not been systematically studied in humans, and absorption rates remain unknown. Chrysolaminarin is a β-1,3-glucan stored within diatom cell walls, which may affect how readily it is digested and absorbed in the human gastrointestinal tract. The structural similarity to immunomodulatory polysaccharides studied in other organisms suggests potential bioactivity, but human absorption and metabolic fate data are lacking.
Why is Thalassiosira pseudonana primarily used in research rather than as a consumer supplement?
T. pseudonana is extensively used in laboratory and research settings because it has a fully sequenced genome and well-characterized biosynthetic pathways, making it ideal for studying marine polysaccharide and carotenoid production. Commercial supplement development has been limited due to the lack of human clinical efficacy trials, established dosing guidelines, and scalable cultivation methods compared to spirulina or chlorella. Most T. pseudonana applications remain focused on biotechnology research and potential future applications rather than direct consumer supplementation.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w thalassiosira-pseudonana-marine-diatom-microalgae curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
